Marker Therapeutics expands cell therapy manufacturing

By The Science Advisory Board staff writers

June 30, 2020 -- Marker Therapeutics plans to establish a new current good manufacturing practice manufacturing facility in Houston to support clinical development of multiantigen targeted (multiTAA)-specific T-cell therapies.

The facility will be designed to meet U.S. Food and Drug Administration guidelines and use scalable modular processes. It will contain 48,5000 sq ft of space for clinical manufacturing and quality control processes. The site is expected to be completed by the end of 2020 and fully operational in 2021.

Marker will manufacture its multiTAA-specific T-cell therapy for its acute myeloid leukemia clinical trial when the facility is operational. Until then, it will continue to manufacture the therapy at the Baylor College of Medicine.

The multiTAA platform is a nongenetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's blood. In early clinical trials the therapy has been well tolerated and shown to enhance the body's own tumor-destroying capabilities. It is among one of the first therapies to demonstrate epitope spreading -- inducing a patient's own T cells to expand for a potentially lasting antitumor effect.

Lyell and Pact partner on T-cell therapy
Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy...
New consortium formed to develop cell-based cancer vaccines
A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic...
Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European...
Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter